Vivinal® Lactoferrin

Lactoferrin is a natural iron-binding milk glycoprotein which has been shown to support the immune system.1,2 Studies with infants suggest that lactoferrin can reduce the risk of respiratory - and gastrointestinal infections. 3-5

Benefits

  • Supports viral and bacterial immune response

  • Can reduce risk of infections

  • Shows immunomodulatory effects

References

  1. Drago-Serrano et al., 2017, Lactoferrin: Balancing ups and downs of inflammation due to microbial infections, International Journal of Molecular Sciences, 18(3):501
  2. Kell et al., 2020, The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria, Frontiers in Immunology, 11:1221
  3. King et al., 2007, A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants, Journal of Pediatric Gastroenterology and Nutrition, 44 (2): 245–51
  4. Chen et al., 2016, Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial, Nutrition, 32 (2), Elsevier Inc.: 222–27
  5. Li et al., 2019, Improved neurodevelopmental outcomes associated with bovine milk fat globule membrane and lactoferrin in infant formula: a randomized, controlled trial, Journal of Pediatrics, 215, Elsevier Inc.: 24–31.e8
  6. Donovan et al., 2016, The role of lactoferrin in gastrointestinal and immune development and function: a preclinical perspective, Journal of Pediatrics, 173, Elsevier Inc.: S16–28
  7. Elzoghby et al., 2020, Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier & targeting ligand, Biomaterials, 263:120355
  8. Gao et al., 2020, Enteral lactoferrin supplementation for preventing sepsis and necrotizing enterocolitis in preterm infants: a meta-analysis with trial sequential analysis of randomized controlled trials, Frontiers in Pharmacology, 11: 1186
  9. Tarnow-Mordi et al., 2020, The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial, The Lancet Child and Adolescent Health, 4 (6): 444–54

Get in touch

Contact our experts
Request a sample Subscribe to our newsletter